Sign Out
Rheumatoid arthritis
Adult: In combination with methotrexate for the treatment of moderate to severe cases in patients who had an inadequate response to DMARDs: 2 mg/kg at weeks 0 and 4, followed by every 8 weeks thereafter. Doses are given via IV infusion over 30 minutes. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Ankylosing spondylitis
Adult: For active cases in patients who had an inadequate response to conventional therapy: 2 mg/kg at weeks 0 and 4, followed by every 8 weeks thereafter. Doses are given via IV infusion over 30 minutes. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Polyarticular juvenile idiopathic arthritis
Child: In combination with methotrexate: ≥2 years 80 mg/m2 at weeks 0 and 4, followed by every 8 weeks thereafter. Doses are given via IV infusion over 30 minutes. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Psoriatic arthritis
Adult: As monotherapy or in combination with methotrexate for the treatment of active cases in patients who had an inadequate response to DMARDs: 2 mg/kg at weeks 0 and 4, followed by every 8 weeks thereafter. Doses are given via IV infusion over 30 minutes. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Rheumatoid arthritis
Adult: In combination with methotrexate for the treatment of moderate to severe cases in patients who had an inadequate response to DMARDs or were not previously treated with methotrexate: 50 mg once monthly given on the same date each month. Review therapy if there is no adequate response after 3-4 doses or within 12-14 weeks of treatment. For patients weighing >100 kg who have inadequate response after 3-4 doses: May increase dose to 100 mg once monthly given on the same date each month considering the increased risk of adverse effects. Review therapy if there is no adequate response after giving 3-4 additional doses of 100 mg. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Ankylosing spondylitis
Adult: As monotherapy or in combination with methotrexate or other nonbiologic DMARDs for active cases in patients who had an inadequate response to conventional therapy: 50 mg once monthly given on the same date each month. Review therapy if there is no adequate response after 3-4 doses or within 12-14 weeks of treatment. For patients weighing >100 kg who have inadequate response after 3-4 doses: May increase dose to 100 mg once monthly given on the same date each month considering the increased risk of adverse effects. Review therapy if there is no adequate response after giving 3-4 additional doses of 100 mg. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Psoriatic arthritis
Adult: As monotherapy or in combination with methotrexate for the treatment of active and progressive cases in patients who had an inadequate response to DMARD: 50 mg once monthly given on the same date each month. Review therapy if there is no adequate response after 3-4 doses or within 12-14 weeks of treatment. For patients weighing >100 kg who have inadequate response after 3-4 doses: May increase dose to 100 mg once monthly given on the same date each month considering the increased risk of adverse effects. Review therapy if there is no adequate response after giving 3-4 additional doses of 100 mg. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Ulcerative colitis
Adult: For treatment of moderate to severe active cases in patients who had an inadequate response to conventional treatment including corticosteroids and 6-mercaptopurine, or azathioprine or are intolerant to or have contraindications for such therapies: Induction: 200 mg, followed by 100 mg at week 2. Maintenance: For patients weighing <80 kg: 50 mg (for those with adequate response) or 100 mg (for those with inadequate response) at week 6, then every 4 weeks thereafter. For patients weighing ≥80 kg: 100 mg every 4 weeks thereafter. Review therapy if there is no adequate response after 4 doses. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Non-radiographic axial spondyloarthritis
Adult: For the treatment of severe, active cases in patients who had an inadequate response or are intolerant to NSAIDs: 50 mg once monthly given on the same date each month. Review therapy if there is no adequate response after 3-4 doses or within 12-14 weeks of treatment. For patients weighing >100 kg who have inadequate response after 3-4 doses: May increase dose to 100 mg once monthly given on the same date each month considering the increased risk of adverse effects. Review therapy if there is no adequate response after giving 3-4 additional doses of 100 mg. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Polyarticular juvenile idiopathic arthritis
Child: In combination with methotrexate for patients who had an inadequate response to previous methotrexate therapy: ≥2 years weighing ≥40 kg: 50 mg once monthly given on the same date each month. Review therapy if there is no adequate response after 3-4 doses or within 12-14 weeks of treatment.
Continue with Google